{
    "clinical_study": {
        "@rank": "78952", 
        "arm_group": {
            "arm_group_label": "Start of Insulin Therapy", 
            "arm_group_type": "Experimental", 
            "description": "Standard Insulin Therapy.  Measurements will be taken before and 2 weeks after the initiation of the Therapy."
        }, 
        "brief_summary": {
            "textblock": "In the proposed study, the investigators examine in older adults with Type 2 diabetes the\n      impact of beginning insulin therapy on the orthostatic drop in blood pressure as well as the\n      response of arterial blood pressure and Doppler measures of cerebral blood flow during\n      upright tilt.  The investigators hypothesize that in older adults with Type 2 diabetes, the\n      cardiovascular effects of insulin would precipitate or worsen orthostatic intolerance not\n      present at baseline."
        }, 
        "brief_title": "Insulin Therapy and Falls Due to Orthostatic Hypotension", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Orthostatic Hypotension", 
            "Diabetes", 
            "Syncope"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Hypotension", 
                "Hypotension, Orthostatic", 
                "Syncope"
            ]
        }, 
        "detailed_description": {
            "textblock": "Before and 2 weeks after the start of standard insulin therapy several tests will be done:\n\n        -  orthostatic hypotension will be tested for with 3 orthostatic maneuvers\n\n        -  vasovagal syncope will be tested with 2 tilt table tests, one augmented with 400ug of\n           nitroglycerin\n\n        -  MCA velocity will be measured with a transcranial doppler\n\n        -  Heart Rate and Blood Pressure will be measured throughout the test with a Finometer and\n           Power Lab on a beat to beat basis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All subjects must be 65 years of age or older\n\n          -  All must have been diagnosed with Type 2 diabetes for at least 5 years\n\n          -  All subjects must be insulin-na\u00efve on recruitment\n\n          -  All subjects must be eligible to start insulin therapy as determined by their\n             diabetologist\n\n        Exclusion Criteria:\n\n          -  Anemia, as determined by serum hematocrit\n\n          -  Abnormal liver function tests\n\n          -  Elevated creatinine\n\n          -  Smoker\n\n          -  Musculoskeletal or neurological condition that would preclude tilt table testing or\n             orthostatic vitals"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914146", 
            "org_study_id": "H13-01375"
        }, 
        "intervention": {
            "arm_group_label": "Start of Insulin Therapy", 
            "description": "Standard Insulin Therapy will be prescribed by the diabetologist. Testing will be done pre and post start of the insulin therapy.", 
            "intervention_name": "Insulin ( Lantus)", 
            "intervention_type": "Drug", 
            "other_name": "Lantus"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes", 
            "Insulin", 
            "Orthostatic Hypotension", 
            "Falls", 
            "Syncope"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "chris.lockhart@vch.ca", 
                "last_name": "Chris Lockhart, BSc", 
                "phone": "604-875-4111", 
                "phone_ext": "68535"
            }, 
            "contact_backup": {
                "email": "kmmadden@mail.ubc.ca", 
                "last_name": "Kenneth Madden, MD", 
                "phone": "604-875-4931"
            }, 
            "facility": {
                "address": {
                    "city": "Vancouver", 
                    "country": "Canada", 
                    "state": "British Columbia", 
                    "zip": "V5Z 1M9"
                }, 
                "name": "UBC VITALiTY Research, Dept. of Medicine, Vancouver Coastal Health Research Institute"
            }, 
            "investigator": {
                "last_name": "Kenneth M Madden, MD MSc FRCPC", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Insulin Therapy and Falls Due to Orthostatic Hypotension (Pilot Study)", 
        "overall_official": {
            "affiliation": "University of British Columbia", 
            "last_name": "Kenneth M Madden, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "defined as a drop in systolic blood pressure greater than 20 mmHg after 3 minutes upright standing", 
            "measure": "1. Presence or absence of orthostatic hypotension", 
            "safety_issue": "Yes", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914146"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "lowest middle cerebral artery flow velocity determined by transcranial Doppler", 
                "measure": "1. The nadir of middle cerebral artery (MCA) velocity", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "description": "The augmented tilt table test will occur after receiving 300 \u03bcg nitroglycerin (GTN), and is a recognized method of testing for risk of vasovagal syncope. The tilt table will be considered positive and aborted prior to the 20 minutes if the subjects have a syncopal spell or demonstrate presyncopal (lightheadedness) symptoms in association with a 30 mm Hg drop in systolic blood pressure.", 
                "measure": "2. The presence or absence of a positive augmented tilt table test", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "description": "lowest systolic blood pressure and diastolic blood pressure during tilt table tests and when they occur.", 
                "measure": "3. The nadir of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during tilt table test.", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }
        ], 
        "source": "University of British Columbia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of British Columbia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}